AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (6.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Targeting the “gut-immune axis”: Bifidobacterium longum subsp. infantis CCFM111 serves as a novel therapeutic for pediatric allergic rhinitis

Xiaoying Zhua,b, Zhangming Peia,b, Yu Wanga,b, Renqiang Yuc, Qiang’er Zhuangd, Yuqing Chene, Xiaomeng Lif, Xiao Leif, Qixiao Zhaia,b, Hao Zhanga,b, Wei Chena,b, Yongxiang Fang( ), Wenwei Lua,b,h( )
State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China
School of Food Science and Technology, Jiangnan University, Wuxi 214122, China
Department of Neonatology, Affiliated Women’s Hospital of Jiangnan University, Wuxi 214002, China
Children’s ENT Department, Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital), Wuxi 214023, China
Children’s ENT Department, Affiliated Women’s Hospital of Jiangnan University (Wuxi Maternal and Child Healthcare Hospital), Wuxi 214002, China
Bayer Healthcare Company Limited, Shanghai 200126, China
China National Center for Food Safety Risk Assessment, Beijing 100020, China
National Engineering Research Center for Functional Food, Jiangnan University, Wuxi 214122, China

Peer review under responsibility of Beijing Academy of Food Sciences.

Show Author Information

Highlights

• CCFM111 alleviated perennial allergic rhinitis in children in a clinical trial

• CCFM111 delayed disease recurrence

• CCFM111 enriched beneficial genera Romboutsia and Fusicatenibacter, linked to clinical benefits

• CCFM111 increased the levels of indole-3-lactic acid and indole-3-carboxaldehyde, correlating with symptom improvement

Abstract

Perennial allergic rhinitis (PAR) is a chronic nasal inflammatory disease that significantly impairs children’s quality of life. Probiotics, capable of restoring microbial balance and modulating immunity, have emerged as promising adjunctive therapies, though evidence in PAR remains limited. In this 20-week randomized, double-blind, placebo-controlled trial, 182 children aged 3-12 years with PAR received either Bifidobacterium longum subsp. infantis CCFM111 (5 × 109 CFU/day, administered as one sachet daily; n = 122) or placebo (maltodextrin; n = 60). After 8 weeks, the probiotic group was further randomized into a short-term subgroup and a long-term subgroup to evaluate the durability of therapeutic effects after probiotic discontinuation. The short-term subgroup (n = 60) discontinued supplementation and received placebo thereafter, whereas the long-term subgroup (n = 62) continued probiotic intake until week 20. The primary outcome was the change in the average modified combined symptom and medication score (ΔmCSMS) from baseline to weeks 7–8. Results showed that at week 8, probiotic treatment significantly reduced ΔmCSMS scores (P < 0.001) and improved immune parameters compared with placebo. In the short-term subgroup, symptom improvement persisted for approximately 10 weeks after discontinuation of probiotics; however, by week 20 (12 weeks post-discontinuation), symptom scores had significantly relapsed compared with the long-term subgroup (P < 0.01). Gut microbiota analysis revealed enrichment of Romboutsia and Fusicatenibacter and enhanced tryptophan metabolism, with increased indole derivatives associated with symptom relief, indicating that CCFM111 may exert its effects through the gut microbiota-tryptophan metabolism axis. No adverse events were observed. These findings suggest that CCFM111 may serve as a safe and effective adjunctive therapy for PAR in children.

Graphical Abstract

Electronic Supplementary Material

Download File(s)
fshw-15-10-9251081_ESM1.docx (41.8 KB)
fshw-15-10-9251081_ESM2.xlsx (34.4 KB)
fshw-15-10-9251081_ESM3.xlsx (35.4 KB)

References

【1】
【1】
 
 
Food Science and Human Wellness
Article number: 9251081

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhu X, Pei Z, Wang Y, et al. Targeting the “gut-immune axis”: Bifidobacterium longum subsp. infantis CCFM111 serves as a novel therapeutic for pediatric allergic rhinitis. Food Science and Human Wellness, 2026, 15(10): 9251081. https://doi.org/10.26599/FSHW.2026.9251081

1128

Views

82

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 11 December 2025
Revised: 02 January 2026
Accepted: 05 February 2026
Published: 17 November 2026
© 2026 Beijing Academy of Food Sciences. Publishing services by Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).